Wednesday, June 21, 2017 1:04:00 PM
CW is extremely pleased with the fact that due to the fortuitous event of Baxalta's being acquired by Shire, MNTA owns the M923 Humira biosimilar 100%. He did, however, mention the difficulty of overcoming the protection afforded by ABBV's more than 100 patents around the drug.
I did relay this group's concerns about the possibility of further dilution, and CW introduced me to Scott Storer the new CFO, who said he doesn't see any need to hit the capital markets again in the near future (with $400MM in the bank and further milestone payments due this year, why would they?).
They treated me like a king, as I was the only stockholder that bothered to attend. BTW, I highly recommend the Kimpton Hotel's valet parking--for anyone considering attending next year.
“It is possible to be a normal decent person and yet to be fully alive.” - George Orwell
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM